Open Access
REVIEW
Harpreet Kaur1,*, Dhrubalochan Rana2, Sowvik Bag2, Paramjeet Singh3
1 University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014, India
2 M. M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, 133207, India
3 Aurobindo Pharma, Durham, NC 27709, USA
* Corresponding Author: Harpreet Kaur. Email:
(This article belongs to the Special Issue: Drug Targets in Oncology: Mechanisms, Challenges, and Innovations)
Oncology Research https://doi.org/10.32604/or.2025.071209
Received 02 August 2025; Accepted 11 December 2025; Published online 04 January 2026
View
Download
Like
Targeting triple-negative breast cancer: A clinical perspective
LAZAR S. POPOVIC, GORANA MATOVINA-BRKO,...mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance
CHIWEN BU, LIGANG ZHAO, LISHAN...Tumor neoantigens: Novel strategies for application of cancer immunotherapy
HANYANG GUAN, YUE WU, LU LI, YABING...